ResMed Inc. (RMD) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RMD SEC filings page.
ResMed Inc. (RMD) reported $5.7B in revenue for fiscal year 2026, up 9.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
ResMed is turning sustained sales growth into expanding margins and internally generated cash while steadily reducing reliance on debt.
The most revealing pattern is profitability outpacing sales: operating margin rose from28.2% in FY2024 to33.4% in FY2026, showing expenses absorbed a smaller share of each additional revenue dollar. At the same time, free cash flow held nearly flat near$1.7B across FY2025–FY2026 despite sharply higher capital spending, indicating that extra earnings were partly redirected into reinvestment rather than appearing as additional distributable cash.
Gross margin climbed from
The balance sheet is less debt-dependent: debt-to-equity roughly halved from FY2025 to FY2026, while FY2026 free cash flow of
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of ResMed Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
ResMed Inc. has an operating margin of 33.4%, meaning the company retains $33 of operating profit per $100 of revenue. This strong profitability earns a score of 94/100, reflecting efficient cost management and pricing power. This is up from 32.8% the prior year.
ResMed Inc.'s revenue grew 9.9% year-over-year to $5.7B, a solid pace of expansion. This earns a growth score of 65/100.
ResMed Inc. carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.10, ResMed Inc. holds $3.10 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 79/100.
ResMed Inc. converts 29.2% of revenue into free cash flow ($1.6B). This strong cash generation earns a score of 94/100.
ResMed Inc. earns a strong 23.1% return on equity (ROE), meaning it generates $23 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 93/100. This is down from 23.5% the prior year.
ResMed Inc. scores 11.18, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($33.1B) relative to total liabilities ($2.4B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
ResMed Inc. passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, ResMed Inc. generates $1.19 in operating cash flow ($1.8B OCF vs $1.5B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
ResMed Inc. generated $1.5B in revenue in Q4 2026. This represents an increase of 8.6% from the same quarter a year earlier. Against the prior quarter it is up 2.3%.
ResMed Inc.'s EBITDA was $493.5M in Q4 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 4.8% from the same quarter a year earlier. Against the prior quarter it is down 11.7%.
ResMed Inc. reported $383.1M in net income in Q4 2026. This represents an increase of 0.8% from the same quarter a year earlier. Against the prior quarter it is down 3.9%.
ResMed Inc. earned $2.64 per diluted share (EPS) in Q4 2026. This represents an increase of 2.3% from the same quarter a year earlier. Against the prior quarter it is down 3.6%.
Cash & Balance Sheet
ResMed Inc. generated $403.5M in free cash flow in Q4 2026, representing cash available after capex. This represents a decrease of 20.6% from the same quarter a year earlier. Against the prior quarter it is down 22.5%.
ResMed Inc. held $1.5B in cash against $399.4M in long-term debt as of Q4 2026.
ResMed Inc. paid $0.60 per share in dividends in Q4 2026. This represents an increase of 13.2% from the same quarter a year earlier. It is unchanged from the prior quarter.
Margins & Returns
ResMed Inc.'s gross margin was 58.8% in Q4 2026, indicating the percentage of revenue retained after direct costs. This is down 2.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.4 percentage points.
ResMed Inc.'s operating margin was 30.7% in Q4 2026, reflecting core business profitability. This is down 3.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.3 percentage points.
ResMed Inc.'s net profit margin was 26.2% in Q4 2026, showing the share of revenue converted to profit. This is down 2.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.7 percentage points.
ResMed Inc.'s ROE was 5.8% in Q4 2026, measuring profit generated per dollar of shareholder equity. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.3 percentage points.
Capital Allocation
ResMed Inc. invested $105.7M in research and development in Q4 2026. This represents an increase of 22.3% from the same quarter a year earlier. Against the prior quarter it is up 12.2%.
ResMed Inc. spent $200.0M on share buybacks in Q4 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 100.0% from the same quarter a year earlier. Against the prior quarter it is up 14.3%.
ResMed Inc. invested $51.1M in capex in Q4 2026, funding long-term assets and infrastructure. This represents an increase of 67.2% from the same quarter a year earlier. Against the prior quarter it is up 51.9%.
RMD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B+8.6% | $1.4B+10.8% | $1.4B+11.0% | $1.3B+9.1% | $1.3B+10.2% | $1.3B+7.9% | $1.3B+10.3% | $1.2B+11.1% |
| Cost of Revenue | $602.4M+14.1% | $540.4M+2.9% | $544.1M+2.5% | $514.8M+1.5% | $527.9M+4.0% | $525.3M+4.2% | $530.8M+2.9% | $507.3M+1.0% |
| Gross Profit | $861.2M+5.0% | $891.0M+16.3% | $878.7M+17.0% | $820.8M+14.4% | $820.1M+14.6% | $766.4M+10.6% | $751.3M+16.1% | $717.2M+19.5% |
| R&D Expenses | $105.7M+22.3% | $94.3M+12.3% | $91.0M+11.8% | $87.3M+9.8% | $86.4M+6.9% | $83.9M+8.9% | $81.4M+10.1% | $79.5M+5.0% |
| SG&A Expenses | $296.3M+10.9% | $285.7M+16.5% | $278.4M+15.2% | $259.2M+8.5% | $267.2M+10.3% | $245.3M+6.7% | $241.6M+8.8% | $239.0M+7.2% |
| Operating Income | $448.7M-1.3% | $499.8M+17.3% | $491.7M+17.8% | $446.5M+15.3% | $454.5M+19.2% | $426.3M+13.8% | $417.2M+51.7% | $387.3M+34.0% |
| EBITDA | $493.5M-4.8% | $558.8M+18.9% | $541.5M+16.8% | $494.2M+14.4% | $518.2M+22.0% | $469.9M+12.4% | $463.7M+45.0% | $432.0M+29.4% |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $775K-94.4% | $1.7M-88.9% |
| Income Tax | $90.7M+15.8% | $103.6M+96.7% | $103.6M+40.5% | $98.3M+36.2% | $78.3M+19.6% | $52.7M-29.7% | $73.7M+45.5% | $72.1M+36.7% |
| Net Income | $383.1M+0.8% | $398.7M+9.2% | $392.6M+13.9% | $348.5M+11.9% | $380.0M+30.0% | $365.0M+21.5% | $344.6M+65.0% | $311.4M+41.9% |
| EPS (Basic) | $2.65+2.3% | $2.74+10.0% | $2.69+14.5% | $2.38+12.3% | $2.59+30.8% | $2.49+22.1% | $2.35+65.5% | $2.12+42.3% |
| EPS (Diluted) | $2.64+2.3% | $2.74+10.5% | $2.68+14.5% | $2.37+12.3% | $2.58+30.3% | $2.48+21.6% | $2.34+64.8% | $2.11+41.6% |
| Diluted Shares (Avg) | N/A | 146M-1.0% | 146M-0.8% | 147M-0.5% | N/A | 147M-0.2% | 147M0.0% | 148M+0.1% |
RMD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.0B+9.7% | $8.8B+16.1% | $8.5B+19.1% | $8.3B+15.0% | $8.2B+18.9% | $7.6B+11.0% | $7.1B+3.4% | $7.2B+7.1% |
| Current Assets | $4.3B+23.4% | $4.1B+26.7% | $3.8B+34.6% | $3.6B+37.3% | $3.5B+48.7% | $3.2B+36.5% | $2.8B+19.3% | $2.6B+14.6% |
| Cash & Equivalents | $1.5B+21.5% | $1.7B+78.0% | $1.4B+171.5% | $1.4B+224.6% | $1.2B+407.4% | $932.7M+292.0% | $521.9M+148.3% | $426.4M+103.9% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $945.8M+2.0% | $911.9M+5.7% | $922.0M+4.5% | $945.8M+3.0% | $927.7M+12.8% | $862.6M+4.0% | $882.1M-5.5% | $918.0M-4.2% |
| Accounts Receivable | $1.0B+10.3% | $998.8M+10.0% | $985.6M+14.6% | $907.3M+11.8% | $939.5M+12.2% | $907.8M+16.5% | $859.9M+17.8% | $811.2M+17.2% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $2.9B-4.5% | $3.0B+6.8% | $3.0B+8.5% | $3.0B+5.5% | $3.0B+7.2% | $2.8B+0.5% | $2.8B-2.0% | $2.9B+2.6% |
| Total Liabilities | $2.4B+7.9% | $2.3B+13.4% | $2.2B+15.6% | $2.2B+7.9% | $2.2B+9.9% | $2.0B-7.5% | $1.9B-22.1% | $2.0B-18.6% |
| Current Liabilities | $1.4B+36.9% | $1.4B+43.7% | $1.2B+46.5% | $1.3B+38.9% | $1.0B+11.9% | $940.5M+21.7% | $852.0M+11.5% | $904.1M+17.3% |
| Non-Current Liabilities | $985.4M-17.0% | $941.2M-12.9% | $934.4M-9.8% | $931.6M-17.1% | $1.2B+8.2% | $1.1B-23.5% | $1.0B-37.5% | $1.1B-34.7% |
| Long-Term Debt | $399.4M-39.3% | $404.2M-39.1% | $403.9M-39.1% | $408.7M-38.8% | $658.4M-5.6% | $663.1M-33.5% | $662.9M-45.5% | $667.6M-50.6% |
| Total Equity | $6.6B+10.3% | $6.5B+17.1% | $6.3B+20.3% | $6.1B+17.8% | $6.0B+22.7% | $5.5B+19.8% | $5.3B+17.2% | $5.2B+22.2% |
| Retained Earnings | $7.3B+19.3% | $7.0B+20.4% | $6.6B+21.0% | $6.3B+21.4% | $6.1B+21.8% | $5.8B+21.2% | $5.5B+21.0% | $5.2B+18.7% |
RMD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $454.6M-15.6% | $554.1M-4.2% | $339.7M+10.1% | $457.3M+40.5% | $538.8M+22.4% | $578.7M+43.9% | $308.6M+13.1% | $325.5M+13.7% |
| Depreciation & Amortization | $44.8M-29.6% | $59.0M+35.0% | $49.9M+7.4% | $47.7M+6.6% | $63.6M+45.7% | $43.7M+0.5% | $46.4M+3.7% | $44.7M-0.5% |
| Stock-Based Compensation | N/A | N/A | N/A | $21.2M+5.0% | N/A | N/A | N/A | $20.2M+8.9% |
| Capital Expenditures | $51.1M+67.2% | $33.7M+61.8% | $28.5M+38.2% | $43.0M+140.8% | $30.6M+22.9% | $20.8M-1.9% | $20.6M-11.6% | $17.8M-40.6% |
| Free Cash Flow | $403.5M-20.6% | $520.5M-6.7% | $311.2M+8.1% | $414.4M+34.7% | $508.2M+22.4% | $557.9M+46.5% | $288.0M+15.4% | $307.7M+20.1% |
| Investing Cash Flow | -$383.7M-186.9% | -$58.0M-82.6% | -$50.9M-38.8% | -$52.6M-2550.0% | -$133.7M-187.5% | -$31.8M+4.1% | -$36.7M+10.8% | $2.1M+101.4% |
| Financing Cash Flow | -$263.2M-60.6% | -$255.2M-77.2% | -$258.3M-75.1% | -$230.3M-52.7% | -$163.9M+58.3% | -$144.1M+57.1% | -$147.5M+38.3% | -$150.8M+0.2% |
| Dividends Paid | $87.1M+12.2% | $87.2M+12.3% | $87.6M+12.7% | $87.8M+12.7% | $77.6M+10.0% | $77.7M+10.2% | $77.7M+9.9% | $77.9M+10.3% |
| Share Buybacks | $200.0M+100.0% | $175.0M+133.3% | $175.0M+133.4% | $150.0M+200.0% | $100.0M+100.0% | $75.0M+50.1% | $75.0M+50.0% | $50.0M |
RMD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 58.8%-2.0pp | 62.3%+2.9pp | 61.8%+3.2pp | 61.5%+2.9pp | 60.8%+2.3pp | 59.3%+1.5pp | 58.6%+3.0pp | 58.6%+4.1pp |
| Operating Margin | 30.7%-3.1pp | 34.9%+1.9pp | 34.6%+2.0pp | 33.4%+1.8pp | 33.7%+2.6pp | 33.0%+1.7pp | 32.5%+8.9pp | 31.6%+5.4pp |
| Net Margin | 26.2%-2.0pp | 27.9%-0.4pp | 27.6%+0.7pp | 26.1%+0.7pp | 28.2%+4.3pp | 28.3%+3.2pp | 26.9%+8.9pp | 25.4%+5.5pp |
| Return on Equity | 5.8%-0.6pp | 6.1%-0.4pp | 6.2%-0.4pp | 5.7%-0.3pp | 6.4%+0.4pp | 6.6%+0.1pp | 6.6%+1.9pp | 6.0%+0.8pp |
| Return on Assets | 4.3%-0.4pp | 4.5%-0.3pp | 4.6%-0.2pp | 4.2%-0.1pp | 4.7%+0.4pp | 4.8%+0.4pp | 4.8%+1.8pp | 4.3%+1.1pp |
| Current Ratio | 3.10-0.3x | 3.01-0.4x | 3.06-0.3x | 2.890.0x | 3.44+0.9x | 3.41+0.4x | 3.33+0.2x | 2.92-0.1x |
| Debt-to-Equity | 0.060.0x | 0.06-0.1x | 0.06-0.1x | 0.07-0.1x | 0.110.0x | 0.12-0.1x | 0.13-0.1x | 0.13-0.2x |
| Asset Turnover | 0.160.0x | 0.160.0x | 0.170.0x | 0.160.0x | 0.160.0x | 0.170.0x | 0.180.0x | 0.170.0x |
| FCF Margin | 27.6%-10.1pp | 36.4%-6.8pp | 21.9%-0.6pp | 31.0%+5.9pp | 37.7%+3.7pp | 43.2%+11.4pp | 22.5%+1.0pp | 25.1%+1.9pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ResMed Inc. RMD | FY2026 | $5.7B | $1.5B | 26.9% | $33.1B | 87/100 |
| Alcon Inc. ALC | FY2010 | $7.2B | $2.2B | 30.8% | $31.0B | — |
| Becton, Dickinson and Co. BDX | FY2025 | $21.8B | $1.7B | 7.7% | $50.1B | 52/100 |
| West Pharmaceutical Services, Inc. WST | FY2025 | $3.1B | $493.7M | 16.1% | $25.8B | 76/100 |
| Hologic Inc HOLX | FY2025 | $4.1B | $565.7M | 13.8% | $17.0B | 69/100 |
| Solventum Corporation SOLV | FY2025 | $8.3B | $1.6B | 18.7% | $14.9B | 50/100 |
Where ResMed Inc. Ranks
Frequently Asked Questions
What is ResMed Inc.'s annual revenue?
ResMed Inc. (RMD) reported $5.7B in total revenue for fiscal year 2026. This represents a 9.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ResMed Inc.'s revenue growing?
ResMed Inc. (RMD) revenue grew by 9.9% year-over-year, from $5.1B to $5.7B in fiscal year 2026.
Is ResMed Inc. profitable?
Yes, ResMed Inc. (RMD) reported a net income of $1.5B in fiscal year 2026, with a net profit margin of 26.9%.
What is ResMed Inc.'s EBITDA?
ResMed Inc. (RMD) had EBITDA of $2.1B in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does ResMed Inc. have?
As of fiscal year 2026, ResMed Inc. (RMD) had $1.5B in cash and equivalents against $399.4M in long-term debt.
What is ResMed Inc.'s gross margin?
ResMed Inc. (RMD) had a gross margin of 61.1% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is ResMed Inc.'s operating margin?
ResMed Inc. (RMD) had an operating margin of 33.4% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is ResMed Inc.'s net profit margin?
ResMed Inc. (RMD) had a net profit margin of 26.9% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
Does ResMed Inc. pay dividends?
Yes, ResMed Inc. (RMD) paid $2.40 per share in dividends during fiscal year 2026.
What is ResMed Inc.'s return on equity (ROE)?
ResMed Inc. (RMD) has a return on equity of 23.1% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is ResMed Inc.'s free cash flow?
ResMed Inc. (RMD) generated $1.6B in free cash flow during fiscal year 2026. This represents a -0.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ResMed Inc.'s operating cash flow?
ResMed Inc. (RMD) generated $1.8B in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are ResMed Inc.'s total assets?
ResMed Inc. (RMD) had $9.0B in total assets as of fiscal year 2026, including both current and long-term assets.
What are ResMed Inc.'s capital expenditures?
ResMed Inc. (RMD) invested $156.3M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does ResMed Inc. spend on research and development?
ResMed Inc. (RMD) invested $378.3M in research and development during fiscal year 2026.
What is ResMed Inc.'s current ratio?
ResMed Inc. (RMD) had a current ratio of 3.10 as of fiscal year 2026, which is generally considered healthy.
What is ResMed Inc.'s debt-to-equity ratio?
ResMed Inc. (RMD) had a debt-to-equity ratio of 0.06 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ResMed Inc.'s return on assets (ROA)?
ResMed Inc. (RMD) had a return on assets of 17.0% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is ResMed Inc.'s P/E ratio?
ResMed Inc. (RMD) trades at 21.7x earnings, its market capitalization divided by net income of $1.5B net income, FY2026. The market capitalization is $33.1B as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ResMed Inc.'s price-to-sales ratio?
ResMed Inc. (RMD) trades at 5.8x sales, its market capitalization divided by revenue of $5.7B revenue, FY2026. The market capitalization is $33.1B as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ResMed Inc.'s Altman Z-Score?
ResMed Inc. (RMD) has an Altman Z-Score of 11.18, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is ResMed Inc.'s Piotroski F-Score?
ResMed Inc. (RMD) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ResMed Inc.'s earnings high quality?
ResMed Inc. (RMD) has an earnings quality ratio of 1.19x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is ResMed Inc.?
ResMed Inc. (RMD) scores 87 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.